XORTX Therapeutics Files June 2024 Report (6-K)
Ticker: XRTX · Form: 6-K · Filed: Jun 12, 2024 · CIK: 1729214
Sentiment: neutral
Topics: regulatory-filing, 6-K
TL;DR
XORTX filed a 6-K on June 12, 2024, confirming CEO Allen Davidoff signed off.
AI Summary
XORTX Therapeutics Inc. filed a Form 6-K on June 12, 2024, to report its activities for the month of June 2024. The filing indicates that the company is a foreign private issuer and will file its annual reports under Form 20-F. Allen Davidoff, the Chief Executive Officer, signed the report on June 11, 2024.
Why It Matters
This filing provides routine updates on the company's status as a foreign private issuer and its reporting obligations. It confirms the CEO's signature on the document.
Risk Assessment
Risk Level: low — This is a routine filing that does not contain new financial information or significant operational updates.
Key Players & Entities
- XORTX Therapeutics Inc. (company) — Registrant
- Allen Davidoff (person) — Chief Executive Officer
- June 12, 2024 (date) — Filing Date
- June 11, 2024 (date) — Signature Date
FAQ
What type of report is XORTX Therapeutics Inc. filing?
XORTX Therapeutics Inc. is filing a Form 6-K, which is a Report of Foreign Private Issuer.
What period does this Form 6-K cover?
This Form 6-K is for the month of June 2024, with a Conformed Period of Report of March 11, 2024.
Who signed the Form 6-K on behalf of XORTX Therapeutics Inc.?
The Form 6-K was signed by Allen Davidoff, Chief Executive Officer.
When was the Form 6-K filed?
The Form 6-K was filed on June 12, 2024.
Does XORTX Therapeutics Inc. file annual reports under Form 20-F or 40-F?
The registrant indicates it files annual reports under cover of Form 20-F.
Filing Stats: 139 words · 1 min read · ~1 pages · Grade level 10.2 · Accepted 2024-06-12 07:00:06
Filing Documents
- f6k_061224.htm (6-K) — 4KB
- exh_991.htm (EX-99.1) — 6KB
- 0001171843-24-003398.txt ( ) — 11KB
From the Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2024 Commission File Number: 001-40858 XORTX Therapeutics Inc. 3710 – 33rd Street NW, Calgary, Alberta, T2L 2M1 Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F [ X ] Form 40-F [ ] SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. XORTX Therapeutics Inc. (Registrant) Date: June 11, 2024 By: /s/ Allen Davidoff Name: Allen Davidoff Title: Chief Executive Officer EXHIBIT INDEX 99.1 News release dated March 11, 2024